FLINT — Diplomat Pharmacy Inc. (NYSE: DPLO), the Flint-based specialty pharmacy, has partnered with New York City-based SMRxT Inc. to begin deploying its Nomi medication adherence system.
ROCHESTER — OptimizeRx Corp. (OTCQB:OPRX), an aggregator of pharmaceutical-sponsored services in electronic health records, appointed company director Gus D. Halas as chairman of the board, effective June 30. He will succeed retiring chairman and company founder, David Harrell.
As the company’s CEO until February of last year, Harrell created the first technology and network to automate customized copay savings and other patient support directly within doctors’ existing electronic prescribing workflow.
FLINT — Diplomat Pharmacy Inc. (NYSE: DPLO) announced it had completed its acquisition of WRB Communications Inc., a health care service center company based in Chantilly, Va.
WRB specializes in relationship management programs for pharmaceutical manufacturers and health care service organizations.
Under the terms of the agreement, Diplomat is paying WRB $24.5 million cash and $4.5 million of Diplomat common stock. Under the terms of a two-year contingent earnout, WRB can earn an additional payout of up to $1 million based upon achievement of earnings-based targets in the 12-month periods ending May 31, 2018, and May 31, 2019. In 2016, WRB generated $15 million in revenue and $2.2 million in adjusted earnings before interest, taxes, depreciation and amortization.
ANN ARBOR — The Ann Arbor pharmaceutical developer Millendo Therapeutics Inc. has announced the initiation of a Phase 2 clinical trial evaluating the safety and efficacy of its drug candidate ATR-101 in patients with endogenous Cushing’s syndrome.
ANN ARBOR — Esperion Therapeutics Inc. (NASDAQ:ESPR), the pharmaceutical startup working on a new class of cholesterol-reducing drugs, provided a drug development update and financial results for 2016.
ANN ARBOR — Esperion Therapeutics Inc. (Nasdaq: ESPR) reported completing enrollment of a new Phase 3 study of about 2,000 patients testing its drug candidate bempedoic acid to treat high cholesterol.
The trial will test the drug’s safety and tolerability in treating patients at high risk of cardiovascular disease whose low-density lipopritein-C, the so-called bad cholesterol, is not adequately controlled with current lipid-modifying therapies.
Top-line results from this study are expected by June 2018.
ANN ARBOR — MichBio, the association for Michigan’s biosciences industry, will welcome hundreds of bioscience researchers, manufacturers, executives and service providers to its Conference and Expo Jan. 18 at the Radisson Plaza Hotel in Kalamazoo.
ANN ARBOR — Esperion Therapeutics Inc. (Nasdaq: ESPR), the Ann Arbor pharmaceutical startup working on a new class of cholesterol-cutting drugs, said it lost $17.4 million or 77 cents a share in the third quarter ended Sept. 30, vs. a loss of $12.8 million or 57 cents a share in the year-earlier period.
The company does not yet have revenue.
For the nine months, the loss was $46 million or $2.04 a share, compared to $36.7 million or $1.68 a share in the first nine months of 2015.
Last month, the company reported positive results in its Phase 1 and Phase 2 clinical studies of its lead drug candidate, bempedoic acid (ETC-1002), in combination iwth high-dose statins. It also amended and expanded a Phase 3 study to include 1,950 patients.
ANN ARBOR — The endocrine drug developer Millendo Therpeutics Inc. this week announced the appointment of three new vice presidents.
* John Kirk as vice president of regulatory affairs
* Naidong Ye. as vice president of chemistry, manufacturing and controls
* Jennifer Minai-Azary as vice president of finance.
ANN ARBOR — The cholesterol-busting drug developer Esperion Therapeutics Inc. (NASDAQ:ESPR) said its Phase 3 clinical trial of drug candidate bempedoic acid will include patients with high cholesterol who are already taking any and all statin drugs.
The move comes based on positive results from Phase 2 trials adding bempedoic acid to patients already taking the statin drug atorvastatin. Adding bempedoic acid lowered cholesterol a further 22 percent compared to placebo. It also demonstrated an incremental reduction of 35 percent in high-sensitivity C-reactive protein (hsCRP), an important marker of the underlying inflammation associated with cardiovascular disease. Bempedoic acid also appeared to be safe and well-tolerated, with no serious adverse events reported.